ARCHIVES

ODAC Endorses Tamoxifen Trial, With Modification to Ensure Enrollment of Women At Higher Risk

This article is from The Cancer Letter archive.

Vol. 17 No. 31 | August 2, 1991

Download PDF Visit The Full Archive

Related Articles

ODAC To Advise FDA on First Biosimilars Application Jan. 7

December 19, 2014

NCI Plans For Research In Breast, Prostate Cancer, Drafted

January 28, 1994

Politics May Play Role In FDA’s Avastin Decision

May 27, 2011

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

January 14, 2005

Two-Month Longer Survival Found With Gliadel Wafer

March 31, 2006

Funding opportunities listed.

January 16, 2004